Literature DB >> 16283123

[Cardiovascular high-risk constellations in primary care. DETECT Study 2003].

L Pieper1, H-U Wittchen, H Glaesmer, J Klotsche, W März, G Stalla, H Lehnert, A M Zeiher, S Silber, U Koch, S Böhler, D Pittrow, G Ruf.   

Abstract

DETECT is a nationwide epidemiological cross-sectional and longitudinal study program in a random probability sample of 3,795 primary care settings (response rate: 60.2%). Based on a target day total assessment of n=55,518 consecutive patients (RR 93.5%) in these settings all patients underwent standardized diagnostic assessment, using self-reporting, clinical interview and laboratory measures. DETECT aims at describing the point prevalence and comorbidity of coronary heart disease (CHD), hyperlipidaemia, arterial hypertension and diabetes mellitus and at identifying the behavioural, clinical, laboratory and psychological risk factors associated with these conditions. A random subset of patients (n=7,519) also completed an extensive standardized laboratory screening program and a 12-month follow-up investigation. Findings reveal a high prevalence of hypertension (36.3%), dyslipidaemia (29.1%), diabetes mellitus (14.6%) and CHD (12.4%) in primary care as well as their close association among each other. The study describes for the first time in greater detail the prevalence of specific disorders and the frequency of high-risk constellations in primary care and allows for the evaluation of various risk scores.

Entities:  

Mesh:

Year:  2005        PMID: 16283123     DOI: 10.1007/s00103-005-1164-9

Source DB:  PubMed          Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz        ISSN: 1436-9990            Impact factor:   1.513


  6 in total

1.  The DETECT adherence score--structure and psychometric exploration of a novel approach to measure adherence to drug and non-drug interventions in primary care.

Authors:  J Klotsche; D M Leistner; L Pieper; D Pittrow; A M Zeiher; H-U Wittchen
Journal:  Int J Methods Psychiatr Res       Date:  2011-06       Impact factor: 4.035

2.  Adverse anthropometric risk profile in biochemically controlled acromegalic patients: comparison with an age- and gender-matched primary care population.

Authors:  C Dimopoulou; C Sievers; H U Wittchen; L Pieper; J Klotsche; J Roemmler; J Schopohl; H J Schneider; G K Stalla
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

3.  Triglycerides and stroke risk prediction: lessons from a prospective cohort study in german primary care patients.

Authors:  Martin Ebinger; Caroline Sievers; Jens Klotsche; Harald J Schneider; Christopher O Leonards; Lars Pieper; Hans-Ulrich Wittchen; Günter K Stalla; Matthias Endres
Journal:  Front Neurol       Date:  2010-11-30       Impact factor: 4.003

4.  Adjusted Troponin I for Improved Evaluation of Patients with Chest Pain.

Authors:  Jes-Niels Boeckel; Lars Palapies; Jens Klotsche; Tanja Zeller; Beatrice von Jeinsen; Maya F Perret; Soeren L Kleinhaus; Lars Pieper; Stergios Tzikas; David Leistner; Christoph Bickel; Günter K Stalla; Hendrik Lehnert; Bertil Lindahl; Hans-Ulrich Wittchen; Sigmund Silber; Stephan Baldus; Winfried Maerz; Stefanie Dimmeler; Stefan Blankenberg; Thomas Münzel; Andreas M Zeiher; Till Keller
Journal:  Sci Rep       Date:  2018-05-24       Impact factor: 4.379

5.  Control of cardiovascular risk factors and its determinants in the general population- findings from the STAAB cohort study.

Authors:  Theresa Tiffe; Martin Wagner; Viktoria Rücker; Caroline Morbach; Götz Gelbrich; Stefan Störk; Peter U Heuschmann
Journal:  BMC Cardiovasc Disord       Date:  2017-11-02       Impact factor: 2.298

6.  Changes in the prevalence, treatment and control of hypertension in Germany? A clinical-epidemiological study of 50.000 primary care patients.

Authors:  Alexander Michael Labeit; Jens Klotsche; Lars Pieper; David Pittrow; Franziska Einsle; Günter Karl Stalla; Hendrik Lehnert; Sigmund Silber; Andreas Michael Zeiher; Winfried März; Martin Wehling; Hans-Ulrich Wittchen
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.